Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

Sanofi SNY announced that the FDA has approved the label expansion ... The SNY drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with ...

In 2022, the global monoclonal antibodies market size was valued at USD 186 billion in 2021. The market is projected to ...

Truist lowered the firm’s price target on Regeneron (REGN) to $1,137 from $1,200 and keeps a Buy rating on the shares after ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon ...

A new study found that risk factors for diabetes in patients with the genetic condition are the same as for those in the ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

The PD-1 and PD-L1 inhibitor market is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031. BURLINGAME, CA, UNITED STATES, October ...